Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Azitra Inc

AZTR ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.17

▼ -4.18%

Market Cap $10.42M · Vol 46.08K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.42M

Micro Cap

Div Yield

N/A

EPS Growth

+92.22%

YoY

RSI (14)

77.14

Momentum

Beta

N/A

vs Market

52W High

$1.09

84.22% below

52W Low

$0.10

72.00% above

Volume

46.08K

Avg 65.21K

P/B

0.75

Price-to-book

ROE

N/A

Return on equity

Free Float

92.41%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Azitra Inc (AZTR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AZTR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.71%

+27.41%

-15.79%

-4.66%

YTD

-35.05%

-78.42%

-99.96%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-10,955,370.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-176.79% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.75
P/FCF	N/A
EPS Growth	+92.22%
Outstanding Shares	60.60M

Technical Indicators

50-Day SMA	$0.15
200-Day SMA	$0.22
RSI (14)	77.14
Beta	N/A
52-Week High	$1.09
52-Week Low	$0.10

Volume Today	46.08K
Avg Daily Volume (30D)	65.21K
Relative Volume	0.71x
Volatility (10D)	69.40
Volatility (30D)	66.80
Free Float	92.41%

Analyst Consensus

BUY

Current Price $0.17

Mean Target $0.78

52W Low$0.10 52W High$1.09

Current

Target

$0.10 $1.09

Current Analyst target

+350.58% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG00GDC73V5

ISINUS05479L3024

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.82% RVMD Revolution Medicines Inc -1.29% ONC BeOne Medicines AG -1.89% 068270.KS Celltrion Inc +0.53% ABVX Abivax SA +3.62%

Company Profile

Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.